Healthleap Raises $38M to Expand AI Hospital Risk Screening
Healthleap raises $38 million to expand AI screening in 50-plus hospitals, flagging hidden risks from malnutrition and delirium for closer clinical review.
Summary
On October 7, 2026, Healthleap disclosed $38 million in financing, comprising an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. Its valuation remains undisclosed. Siblings Jemima and Josiah Meyer founded the company in South Africa in 2022, initially offering Jemima’s clinical nutrition tool for dietitians before pivoting to hospital risk screening. Healthleap now screens for malnutrition and delirium in more than 50 hospitals. Programs covering aspiration pneumonia, pressure ulcers and congestive heart failure readmission are undergoing further clinical validation.
Healthleap connects to electronic health records and uses language models to extract clinical concepts, including recent weight loss and swallowing difficulty, from notes. Each night it analyzes every adult inpatient’s labs, vital signs, weights, medications, diet orders, diagnoses and notes, combining them in risk models. Each morning, care teams receive risk scores and patient trends through existing workflows and a dashboard. The software flags cases for review rather than diagnosing them. Research estimates 20% to 50% of hospital inpatients are malnourished, increasing risks including longer stays, poor wound healing, infections, morbidity and mortality.
Hospital partners grew from three to more than 50 over the past year, while revenue rose more than tenfold, although Healthleap withheld figures. Customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Three-year contracts are priced by licensed bed count, with outcome-based pricing tied to finance-validated returns. Healthleap says every customer achieved at least five times hard ROI, sometimes exceeding 20 times annual total ROI. Its Hospital of the University of Pennsylvania program generated $23.8 million in annualized impact, including $6.3 million in reimbursement and $17.5 million from shorter stays. Funding will support engineering, product, sales and customer success as Healthleap targets more than 40 major conditions plus outpatient and home care.
Positives
- $38 million in seed and Series A funding gives Healthleap capital to expand engineering, product, sales and customer success.
- Hospital partners increased from three to more than 50 in one year, while revenue grew more than tenfold.
- Every customer achieved at least five times hard ROI, with some exceeding 20 times annual total ROI, Healthleap says.
- $23.8 million in annualized impact at the Hospital of the University of Pennsylvania included $17.5 million from shorter stays.
- More than 40 major conditions, outpatient care and home care are included in Healthleap’s planned expansion.
Risks & concerns
- Healthleap’s software only flags patients for clinical review and does not provide diagnoses.
- Aspiration pneumonia, pressure ulcer and congestive heart failure readmission programs still require further clinical validation.
- Healthleap has disclosed neither its valuation nor specific revenue despite reporting more than tenfold growth.
- An estimated 20% to 50% of hospital inpatients are malnourished, with links to longer stays, infections, complications and higher mortality.